Prism Medico and Pharmacy Ltd reported zero revenue from operations and a net loss of ₹0.06 crore for Q1 FY27. Paid-up capital significantly increased to ₹13.56 crore.
Prism Medico Suffers Nil Revenue, Swings to Net Loss in Q1 FY27
Nil Revenue from Operations, Net Loss of ₹0.06 crore
Reader Takeaway: Zero revenue raises business continuity concerns, while increased equity needs clarification.
What just happened
Prism Medico and Pharmacy Ltd reported nil revenue from operations for the quarter ended June 30, 2026. This marks a significant drop from ₹1.59 crore in the same period last year. Consequently, the company swung to a net loss of ₹0.06 crore (₹5.83 lakh), compared to a profit of ₹0.66 crore in Q1 FY26.
Why this matters
The complete absence of operational revenue is a major red flag for investors, raising serious questions about the company's current business activities and its ability to generate income. The shift from profit to loss further amplifies these concerns.
The backstory
In the previous year's comparable quarter (Q1 FY26), Prism Medico had generated ₹1.59 crore in revenue and reported a profit of ₹0.66 crore. The current results show a stark reversal.
What changes now
Investors will be closely watching for any management explanations regarding the drastic drop in operational activity. The substantial increase in paid-up equity capital to ₹13.56 crore from ₹6.06 crore in the prior year also requires clarification, potentially indicating equity dilution.
Risks to watch
The primary risk is the ongoing lack of business operations, which directly impacts revenue generation and future profitability. The reasons behind the significant increase in paid-up equity capital need to be understood to assess potential dilution for existing shareholders.
Peer comparison
(No peer comparison data available in the filing)
Context metrics (time-bound)
Paid-up Equity Capital for Q1 FY27 stood at ₹13.56 crore, compared to ₹6.06 crore in Q1 FY26.
What to track next
Investors should closely monitor future disclosures from Prism Medico for any updates on operational revival, management commentary on the financial results, and the specific details behind the increased equity capital.